SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

Stopped early · Phase 2

Conditions studied: Colorectal Cancer

In brief

Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic or locally recurrent colorectal cancer. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor.

Key facts

Study ID

NCT00006001

Run by

National Cancer Institute (NCI)

People needed

37

Starts

2000-08-01

Expected to finish

2009-08-01

Last updated by the study team

2013-06-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Illinois at Chicago — Chicago, Illinois, United States
• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Louis A. Weiss Memorial Hospital — Chicago, Illinois, United States
• Cancer Care Specialists of Central Illinois, S.C. — Decatur, Illinois, United States
• Evanston Northwestern Health Care — Evanston, Illinois, United States
• Division of Hematology/Oncology — Park Ridge, Illinois, United States
• Oncology/Hematology Associates of Central Illinois, P.C. — Peoria, Illinois, United States
• Central Illinois Hematology Oncology Center — Springfield, Illinois, United States
• Fort Wayne Medical Oncology and Hematology, Inc. — Fort Wayne, Indiana, United States
• Michiana Hematology/Oncology P.C. — South Bend, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.